Skip to content

Effect of Glutamine on Reducing Myocardial Damage

Evaluation of Oral Glutamine Administration on Reduction of Myocardial Dmage After Open Heart Surgery, a Prospective Randomized Clinical Trial Study

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20151109024975N10
Enrollment
106
Registered
2018-08-29
Start date
2018-09-21
Completion date
Unknown
Last updated
2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute coronary syndrome. Acute coronary thrombosis not resulting in myocardial infarction

Interventions

Intervention 1: Intervention group: A dose of 0.5 g / kg of glutamine powder is administered orally once a day during the ICU for patients. Intervention 2: Control group: Patients in the control group

Sponsors

Sari University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Age over 18 years Candidate for open heart surgery Preoperative sinus rhythm Normal function of liver, renal system, pulmonary system and thyroid

Exclusion criteria

Exclusion criteria: Emergency patients Serious water and electrolyte disorders Unwillingness to co-operate with the patient History of chronic lung, liver, kidney and thyroid diseases and heart failure Age over 80 years Pregnant and lactating women Patients who are hypersensitive to glutamine or who are banned in any way by their administration of glutamine Total Bilirubin more than 10 mg / dL Creatinine clearance less than 30 ml / min Absolute Absence of Intestinal Feeding

Design outcomes

Primary

MeasureTime frame
Myocardial injury after open heart surgery. Timepoint: The day before the surgery (before the intervention) and the first and second days after surgery. Method of measurement: SOFA score.

Secondary

MeasureTime frame
Duration of admission to ICU. Timepoint: Duration of admission. Method of measurement: Patients follow up.;Duration of hospitalization. Timepoint: Duration of admission. Method of measurement: Patients follow up.;Mortality. Timepoint: Duration of admission. Method of measurement: Patients follow up.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactGohar Eslami

Sari University of Medical Sciences

g.eslami@mazums.ac.ir+98 11 3354 3695

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026